Prostate Cancer: Long-Term Safety of Lutetium (177Lu) Treatment

We are investigating the long-term safety of lutetium (177Lu) vipivotide tetraxetan in adults with prostate cancer. This study aims to identify potential risks and serious side effects over time.

>2 years Monitoring phase (IV)No Placebo Cost Reimbursement Partially Remote Standard Medicines InjectionOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Pluvicto

Pluvicto is a radioactive medicine used to target and treat advanced prostate cancer that has spread and no longer responds to hormone therapy.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Lutetium (177lu) Vipivotide Tetraxetan

Lutetium (177Lu) vipivotide tetraxetan is a targeted radioactive treatment that delivers radiation directly to prostate cancer cells with a protein called PSMA.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Ordensklinikum Linz GmbH

#2000: Department of Urology

Linz, Austria

Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken

#2002: University Hospital for Urology

Vienna, Austria

Universitair Ziekenhuis Gent

#2050: Urologie

Ledeberg, Belgium

Sponsor: Novartis Pharma AG

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.